33
Participants
Start Date
July 19, 2022
Primary Completion Date
July 1, 2025
Study Completion Date
July 1, 2027
RT
"The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy~/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed."
RECRUITING
AOU Careggi, Florence
Azienda Ospedaliero-Universitaria Careggi
OTHER